Camelia Iancu-Rubin, PhD
- ASSOCIATE PROFESSOR | Medicine, Hematology and Medical Oncology
Research Topics:Blood, Cancer, Cell Biology, Differentiation, Fibrosis, Hematopoiesis, Leukemia, Molecular Biology, Translational Research
Dr. Iancu-Rubin completed her Bachelor and Master Degrees at the University of Bucharest in Romania in 1989 and 1992, respectively. She pursued a career in clinical laboratory medicine and teaching until 1997 when she was awarded a Fulbright Fellowship in biomedical sciences. As Fulbright Scholar she completed her graduate studies at the Graduate School of Biomedical Sciences at Mount Sinai Medical Center in New York. Dr. Iancu-Rubin received her Ph.D. in Life Sciences in 2000 and did her post-doctoral training in hematology. Currently, she is faculty member of the NCI-designated Tisch Cancer Institute and of the Department of Medicine at Icahn School of Medicine at Mount Sinai and the Director of Hematological Malignancies Tissue Bank. Dr. Iancu-Rubin has been investigator on NIH-funded, foundation and institutional projects as well as on industry-sponsored preclinical and clinical studies. She is conducting research independently and within the MPN and NYSTEM Research Consortiums. Her research focuses on normal and malignant hematopoiesis and megakaryopoiesis with emphasis on pre-clinical and clinical evaluation of drug-based and cellular therapies for patients with hematological malignancies. Dr. Iancu-Rubin’s research has been recognized in highly ranked peer-reviewed publications and her expertise has been sought by multiple collaborators.
MS, University of Medicine and Pharmacy
PhD, University of Bucharest
Mount Sinai School of Medicine
The Tisch Cancer Institute Development Award
Mentored Scientist Career Development Award
Fulbright Felowship in Biomedical Sciences
- normal and malignant hematopoiesis
- megakaryocytes, platelets and hematopoietic stem cells biology
- mechanisms of drug-related thrombocytopenia
- development of therapeutic approaches for thrombocytopenia
- mechanisms underlying pathogenesis of myeloproliferative neoplasms
- pre-clinical evaluation of treatment approaches for myeloproliferative neoplasms
Dr. Iancu-Rubin is involved in clinical studies in hematological cancer and is the Scientific Director of Hematological Malignancies Tissue Bank of the Tisch Cancer Institute http://icahn.mssm.edu/research/institutes/tisch-cancer-institute/cancer-research/shared-resources/hematological-malignancies-tissue-bank
Mosoyan G, Kraus T, Ye F, Eng K, Crispino JD, Hoffman R, Iancu-Rubin C. Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis. Leukemia 2017 Nov; 31(11).
Elagib KE, Lu CH, Mosoyan G, Khalil S, Zasadzińska E, Foltz DR, Balogh P, Gru AA, Fuchs DA, Rimsza LM, Verhoeyen E, Sansó M, Fisher RP, Iancu-Rubin C, Goldfarb AN. Neonatal expression of RNA-binding protein IGF2BP3 regulates the human fetal-adult megakaryocyte transition. The Journal of clinical investigation 2017 Jun; 127(6).
Choi DC, Tremblay D, Iancu-Rubin C, Mascarenhas J. Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms. Annals of hematology 2017 Jun 96(6).
Ceglia I, Dueck AC, Masiello F, Martelli F, He W, Federici G, Petricoin EF, Zeuner A, Iancu-Rubin C, Weinberg R, Hoffman R, Mascarenhas J, Migliaccio AR. Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis. Experimental hematology 2016 Dec; 44(12).
Iancu-Rubin C, Hoffman R. Role of epigenetic reprogramming in hematopoietic stem cell function [review]. Current opinion in hematology 2015 Jul; 22(4).
Atweh GF, Iancu-Rubin C. p27(Kip1) and STMN1: partners again?. Cell cycle (Georgetown, Tex.) 2014 13(20).
Iancu-Rubin C, Mosoyan G, Glenn K, Gordon RE, Nichols GL, Hoffman R. Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis. Experimental hematology 2014 Feb; 42(2).
Iancu-Rubin C, Mosoyan G, Wang J, Kraus T, Sung V, Hoffman R. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap.. Exp Hematol 2013; 41(2): 155-166.
Iancu-Rubin C, Gajzer D, Mosoyan G, Feller F, Mascarenhas JE, Hoffman R. Panobinostat (LBH589)-induced acetylation of tubulin impairs megakaryocyte maturation and platelet formation.. Exp Hematol 2012 July; 40(7): 564-574.
Iancu-Rubin C, Gajzer D, Tripodi J, Gordon R, Hoffman R, Atweh GF. Down-regulation of stathmin expression is required for megakaryocyte maturation and platelet production. Blood 2011 Apr; 17(17).
Chen J, Peterson KF, Iancu-Rubin C, Bieker JJ. Design of embedded chimeric peptide nucleic acids that efficiently enter and accurately reactivate gene expression in vivo. Proceedings of the National Academy of Sciences of the United States of America 2010 Sep; 107(39).
Iancu-Rubin C, Nasrallah CA, Atweh GF. Stathmin prevents the transition from a normal to an endomitotic cell cycle during megakaryocytic differentiation. Cell cycle 2005 Dec; 93(12).
Rubin CI, Atweh GF. The role of stathmin in the regulation of the cell cycle. J of Cell Sci 2004 Oct; 93(2).
Iancu C, Mistry SJ, Arkin S, Wallenstein S, Atweh GF. Effects of Stathmin Inhibition on the Mitotic Spindle. J of Cell Sci 2001; 114(5): 3537-3541.
Iancu C, Mistry SJ, Wallenstein I, Atweh G. Taxol and Anti-Stathmin Therapy: A Synergistic Combination that Targets the Mitotic spindle. Cancer Research 2000; 60(13): 3537-3541.